Elsevier

Thrombosis Research

Volume 36, Issue 4, 15 November 1984, Pages 281-292
Thrombosis Research

Complement inhibitory and anticoagulant activities of fractionated heparins

https://doi.org/10.1016/0049-3848(84)90319-0Get rights and content

Abstract

Almost monodisperse heparin fractions (Mw/Mn < 1.1) were obtained by gel filtration of a commercial heparin. These fractions were assayed for anticoagulant activity (thrombin times and APTT), chromogenic anti-factor Xa activity, inhibitory activity for the human classical complement pathway, carboxyl group content and total sulfate content. Linear relationships were observed between the molecular weight of the heparin fractions and the anticoagulant activities as determined by thrombin time- and APTT-assay and the classical complement pathway inhibitory activity. On the other hand a hyperbolic-like relationship was observed between the molecular weight of the heparin fractions and the chromogenic anti-factor Xa activity. The heparin fractions did not show significant differences with respect to the carboxyl group and total sulfate content. Low- and high affinity heparin fractions were obtained by affinity chromatography using immobilized AT III. High- and low-affinity fractions greatly differed not only with respect to their APTT activity, but also where their complement-inhibitory activities were concerned. The latter in contrast to literature data available. These differences could not be explained by the observed differences in molecular weight of high and low affinity heparin respectively.

References (35)

  • D. Ogston et al.

    Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin

    Thromb. Res.

    (1976)
  • L.B. Jaques

    Heparin: an old drug with a new paradigm

    Science

    (1977)
  • I. Bjork et al.

    Mechanism of the anticoagulant action of heparin

    Molecular and Cellular Biochemistry

    (1982)
  • J.M. Weiler et al.

    Modulation of the formation of the amplification convertase of complement, C3bBb, by native and commercial heparin

    J. Exp. Med.

    (1978)
  • M.D. Kazatchkine et al.

    Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b

    J. Exp. Med.

    (1979)
  • P. Bianchini et al.

    Pharmacological activities of heparins obtained from different tissues

  • M.D. Kazatchkine et al.

    Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase

    J. Clin. Invest.

    (1981)
  • Cited by (25)

    View all citing articles on Scopus
    View full text